Morocco
Tuberculosis profile
Population  2012 33 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3 (1.4–5.1) 9.2 (4.4–16)
Mortality (HIV+TB only) 0.096 (0.081–0.11) 0.3 (0.25–0.35)
Prevalence  (includes HIV+TB) 46 (19–83) 140 (58–257)
Incidence  (includes HIV+TB) 33 (29–38) 103 (90–117)
Incidence (HIV+TB only) 0.59 (0.51–0.67) 1.8 (1.6–2)
Case detection, all forms (%) 86 (75–98)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 11 572 (42) Relapse 1 198 (61)
Smear-negative 2 343 (9) Treatment after failure 247 (13)
Smear-unknown / not done 0 (0) Treatment after default 415 (21)
Extrapulmonary 13 522 (49) Other 102 (5)
Other 0 (0)      
Total new 27 437   Total retreatment 1 962  
           
Other (history unknown) 0        
Total new and relapse 28 635   Total cases notified 29 399  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.4 1.6 0.9
Age < 15 131 101 1 768
Laboratories 2012
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 2.2
Drug susceptibility testing (per 5 million population) 0.3
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 80   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 83  
Retreatment 66  
TB/HIV 2012 Number (%)
TB patients with known HIV status 5 827 (20)
HIV-positive TB patients 357 (6)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 357 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 357 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0.48 (0.15–1.1) 12 (7.8–18)
MDR-TB cases among notified pulmonary
TB cases
66 (22–150) 240 (150–350)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 103 (<1%) 416 (21%) 519
Laboratory-confirmed MDR-TB cases 8 72 80
Patients started on MDR-TB treatment     138
Financing TB control 2013
National TB programme budget (US$ millions) 18
% Funded domestically 88%
% Funded internationally 10%
% Unfunded 2%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-21 Data: www.who.int/tb/data